Duke University: Glioma trials

The registry lists 39 Glioma studies with Duke University as lead sponsor. 1 are open to participants now and 13 have results posted.

Early Phase 1 2Phase 1 11Phase 2 19No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252RecruitingNCT06126744Phase 1
• Seizure Prophylaxis in Patients With Glioma or Brain MetastasisTerminatedNCT03436433Phase 2Results posted
• Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and TemozolomideCompletedNCT02991456Phase 2Results posted
• Bevacizumab Beyond Progression (BBP)CompletedNCT01740258Phase 2Results posted
• Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma PatientsCompletedNCT01738646Phase 2Results posted
• Radiosurgery and Avastin for Recurrent Malignant GliomasCompletedNCT01017250Not applicableResults posted
• Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for GlioblastomaCompletedNCT01004874Phase 2Results posted
• Intravenous Palonosetron With Radiotherapy and Concomitant TemozolomideCompletedNCT00900757Phase 2Results posted
• A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)TerminatedNCT00735436Phase 2Results posted
• Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma MultiformeCompletedNCT00672243Phase 2Results posted
• Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)CompletedNCT00671970Phase 2Results posted
• Phase II Avastin + Bortezomib for Patients With Recurrent Malignant GliomaCompletedNCT00611325Phase 2Results posted
• Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant GliomaCompletedNCT00501891Phase 2Results posted
• A Pilot Study of Dronabinol for Adult Patients With Primary GliomasCompletedNCT00314808Phase 1Results posted
• GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBMSuspendedNCT05695976
• Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)Active, not recruitingNCT05634707Early Phase 1
• The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics EvaluationCompletedNCT04937413Early Phase 1
• Mindfulness Meditation in Glioma PatientsCompletedNCT03915912Not applicable
• Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating FieldsCompletedNCT03501134
• Early Palliative Care Intervention in Malignant GliomaCompletedNCT03471546Not applicable
• LITT Palliative Treatment for Patients With Malignant GliomasWithdrawnNCT03176160
• Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma PatientsWithdrawnNCT01952886Phase 2
• Coping With High Grade GliomaTerminatedNCT00815152Not applicable
• Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + TemozolomideCompletedNCT00616005Phase 2
• Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant GliomaCompletedNCT00613093Phase 2
• PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant GliomasCompletedNCT00612651Phase 1
• Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic GliomasCompletedNCT00612638Phase 1
• Imatinib Mesylate and Temozolomide in Treating Patients With Malignant GliomaCompletedNCT00354068Phase 1
• Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant GliomaCompletedNCT00352521Phase 2
• Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic GliomaCompletedNCT00006474Phase 1
• Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant GliomaCompletedNCT00005951Phase 1
• Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive GliomaCompletedNCT00005081Phase 2
• Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade GliomaCompletedNCT00003467Phase 2
• Temozolomide in Treating Patients With Progressive Low-Grade GliomaCompletedNCT00003466Phase 2
• Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade GliomasCompletedNCT00003463Phase 1
• Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant GliomaCompletedNCT00002988Phase 1
• Chemotherapy in Treating Patients With Recurrent Malignant GliomaCompletedNCT00002986Phase 1
• Monoclonal Antibody Therapy in Treating Patients With Recurrent GliomasCompletedNCT00002753Phase 1
• Carboplatin in Patients With Progressive GliomasCompletedNCT00002749Phase 2